Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00171405 · ClinicalTrials.gov registry record · Phase 3

A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg

A Phase 3 study of Hypertension, sponsored by Novartis.

Completed
Registry status
Phase 3
Development phase
250
Enrollment target
10
Study locations

NCT00171405: Completed Phase 3 study of Hypertension, sponsored by Novartis.

NCT00171405 is a Phase 3 study of Hypertension that has completed, run by Novartis. The registered enrollment target is 250 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (93% lower). The trial reports 10 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00171405, a Phase 3 study of Hypertension, has completed, sponsored by Novartis.

COMPLETED
Registry status
Phase 3
Development phase
250 participants
Enrollment target
10
Study locations

Study Summary

The purpose of this study is to collect the long-term (12 months) safety data on aliskiren 300 mg when taken in combination with HCTZ 25 mg.

Conditions Studied

Hypertension

Interventions

  • DRUG aliskiren

Study Locations (10)

Other

  • Investigative Site - Deurne
  • Investigative Site - Ste-Fov
  • Investigative Site - Krassel
  • Investigative Site - Broni
  • Investigative Site - Rotterdam
  • Investigative Site - Lima
  • Investigative Site - Moscow
  • Investigative Site - Basel
  • Investigative Site - London

New Jersey

  • Investigative Site - East Hanover

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2005-06
Est. Completion 2006-02
Phase Phase 3
Novartis

265 total trials

What the finished NCT00171405 record still lists

NCT00171405 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which aliskiren is the first listed.

NCT00171405 lists 10 locations in 2 states (Other, New Jersey).

Frequently Asked Questions

What is clinical trial NCT00171405 about?

NCT00171405 is a clinical study titled "A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg". The purpose of this study is to collect the long-term (12 months) safety data on aliskiren 300 mg when taken in combination with HCTZ 25 mg.

What is the current status of trial NCT00171405?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2005-06. Estimated completion is 2006-02.

What conditions does trial NCT00171405 study?

This clinical trial studies the following conditions: Hypertension.

What interventions are being tested in trial NCT00171405?

The interventions under investigation include: aliskiren (DRUG).

Who is sponsoring clinical trial NCT00171405?

This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00171405 being conducted?

This trial has 10 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00171405's enrollment target sits among peer trials

250 194th of 470 higher than 274 of 470 other Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00483249 · 250 participants · NA

    Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm

  • NCT00777712 · 250 participants

    Mechanisms Underlying Impaired Diabetic Wound Healing

  • NCT01451502 · 250 participants · NA

    Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

  • NCT01771718 · 250 participants

    Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00171405, the US trial registry maintained by the National Library of Medicine. NCT00171405 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.